XML 37 R7.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating activities:    
Net (loss) income $ (42,850) $ 27,187
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:    
Depreciation 212 207
Amortization of right-of-use operating lease assets 226 330
Amortization of intangibles 1,462 1,446
Amortization of premium/discount on investment securities, net 311 (229)
Non-cash sublicensing expense   75,000
Stock-based compensation expense 7,282 18,560
Changes in operating assets and liabilities:    
Accounts receivable (177) (5,672)
Other current and long-term assets (2,664) (1,327)
Inventories (2,382) (272)
Accounts payable 156 (4,673)
Receivable from Ionis Pharmaceuticals, Inc. 620 (26,165)
Income tax receivable (129)  
Accrued compensation (5,797) (2,283)
Accrued liabilities 1,729 2,063
Income taxes payable (771) (56)
Deferred revenue (1,333) (5,524)
Net cash (used in) provided by operating activities (44,105) 78,592
Investing activities:    
Purchases of short-term investments (154,910) (13,858)
Proceeds from maturity of short-term investments 53,800 59,689
Purchases of property, plant and equipment (209) (1,031)
Net cash (used in) provided by investing activities (101,319) 44,800
Financing activities:    
Proceeds from exercise of common stock options and employee stock purchase plan issuances 1,945 4,588
Distribution to Ionis Pharmaceuticals, Inc.   (13,492)
Payments of tax withholdings related to exercise of employee stock awards (76)  
Net cash provided by (used in) financing activities 1,869 (8,904)
Effect of exchange rates on cash 9 85
Net (decrease) increase in cash and cash equivalents (143,546) 114,573
Cash, cash equivalents and restricted cash at beginning of period 309,250 88,838
Cash, cash equivalents and restricted cash at end of period 165,704 203,411
Cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets:    
Cash and cash equivalents 163,320 201,027
Restricted cash included in deposits and other assets 2,384 2,384
Cash, cash equivalents and restricted cash at end of period 165,704 $ 203,411
Ionis [Member]    
Supplemental disclosures of non-cash financing activities:    
Purchase of property, plant and equipment included in payable to Ionis Pharmaceuticals, Inc. $ 179